SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Safety of meningococcal group B vaccination in hospitalised premature infants.

Kent, A; Beebeejaun, K; Braccio, S; Kadambari, S; Clarke, P; Heath, PT; Ladhani, S; National Neonatal Audit Network (2019) Safety of meningococcal group B vaccination in hospitalised premature infants. Arch Dis Child Fetal Neonatal Ed, 104 (2). F171-F175. ISSN 1468-2052 https://doi.org/10.1136/archdischild-2017-314152
SGUL Authors: Heath, Paul Trafford Ladhani, Shamez Nizarali

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (369kB) | Preview

Abstract

OBJECTIVES: To assess the risk of significant adverse events in premature infants receiving the novel 4-component group B meningococcal vaccine (4CMenB) with their routine immunisations at 2 months of age. PARTICIPANTS, DESIGN AND SETTING: In December 2015, Public Health England requested neonatal units across England to voluntarily participate in a national audit; 19 units agreed to participate. Anonymised questionnaires were completed for infants receiving 4CMenB alongside their routine immunisations. For comparison, a historical cohort of premature infants receiving their primary immunisations without 4CMenB or paracetamol prophylaxis was used. MAIN OUTCOME MEASURES: Paracetamol use; temperature, cardiovascular, respiratory and neurological status before and after vaccination; and management and investigations postvaccination, including serum C reactive protein levels, infection screens and antibiotic use. RESULTS: Complete questionnaires were returned for 133 premature infants (<35 weeks' gestation) who received their first dose of 4CMenB at 8 weeks of age, including 108 who received prophylactic paracetamol according to national recommendations. Overall, 7% (8/108) of infants receiving 4CMenB with paracetamol had fever (>38°C) after vaccination compared with 20% (5/25) of those receiving 4CMenB without paracetamol (P=0.06) and none of those in the historical cohort. There were no significant differences between cohorts in the proportion of infants with apnoea, bradycardia, desaturation and receiving respiratory support after vaccination. CONCLUSIONS: 4CMenB does not increase the risk of serious adverse events in hospitalised premature infants. This audit supports the current national recommendations to offer 4CMenB with other routine vaccinations and prophylactic paracetamol to premature infants at their chronological age.

Item Type: Article
Additional Information: This article has been accepted for publication in Archives of Disease in Childhood Fetal and Neonatal Edition following peer review. The definitive copyedited, typeset version Kent A, Beebeejaun K, Braccio S The National Neonatal Audit Network, et al Safety of meningococcal group B vaccination in hospitalised premature infants Archives of Disease in Childhood - Fetal and Neonatal Edition 2019;104:F171-F175 is available online at: http://dx.doi.org/10.1136/archdischild-2017-314152
Keywords: 4cmenb vaccine, apnoea, fever, infant, premature, 4cmenb vaccine, apnoea, fever, infant, premature, Pediatrics, 1114 Paediatrics And Reproductive Medicine
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Arch Dis Child Fetal Neonatal Ed
ISSN: 1468-2052
Language: eng
Dates:
DateEvent
19 February 2019Published
10 April 2018Published Online
8 February 2018Accepted
Publisher License: Publisher's own licence
PubMed ID: 29636385
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/109748
Publisher's version: https://doi.org/10.1136/archdischild-2017-314152

Actions (login required)

Edit Item Edit Item